サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ライム病診断薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1345431

ライム病診断薬の世界市場-2023年～2030年

Global Lyme Disease Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ライム病診断薬の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

ライム病診断薬の世界市場は、2022年に16億米ドルに達し、2023-2030年の予測期間中にCAGR 4.3%で成長し、2030年には22億米ドルに達すると予測されています。

ライム病診断検査は、血液または脳脊髄液（CSF）のサンプルから感染の兆候を調べるものです。髄液は脳や脊髄の中や周囲を流れる透明な液体です。この検査では、ライム病の原因となる細菌と闘うために免疫系が作る抗体のサンプルを調べます。これらの診断検査は、感染に反応して免疫系が産生する抗体を特定するものです。ライム病診断薬は、患者が感染したクロアシマダニにさらされているかどうかの可能性を予測します。

ライム病診断薬市場の調査分析は、量的および質的データを含む市場の詳細な見通しを提供します。市場セグメンテーションに基づく世界市場の展望と予測を提供します。また、世界のライム病診断薬市場規模や成長機会、最新動向、2030年までの予測も提供しています。

すべての地域の中で、北米地域が予測期間中、世界のライム病診断薬市場で最大のシェアを占めると予想されます。北米は世界のライム病診断薬市場において支配的な地位を占めています。血清学的検査分野が市場シェアにおいて重要な位置を占めています。

ダイナミクス

技術進歩の拡大と新製品の導入が市場成長を牽引する見込み

世界のライム病診断薬市場の成長は、市場に投入された様々な新しい技術革新や製品など、いくつかの要因によって牽引されています。ライム病協会によると、ライム病は世界的に最も一般的なダニ媒介性細菌感染症です。ライム病市場は、ライム病の正確な診断のための新しい有効な診断検査の発売と認可を目の当たりにしています。

例えば、2022年6月15日、適応免疫系の遺伝学を病気の診断と治療のための臨床製品に変換することを目的とした商業段階のバイオテクノロジー企業であるAdaptive Biotechnologies Corporationは、T-Detect Lymeの発売を発表しました。これは、成長著しいT-Detectフランチャイズから発売される、同社にとって2番目の検査です。

ライム病診断のための新製品の発売や様々な製品のイントロダクションの増加は、市場の成長を高めると予想されます。例えば、2022年10月26日、デジタル診断会社のixlayerは、CVS Healthブランドの家庭用サンプル採取キットを製造すると発表しました。ixlayerのキットは、ライム病、ビタミンDレベル、甲状腺機能、性感染症の検査が可能です。したがって、上記の要因が市場成長を促進すると予想されます。

政府によるイニシアチブの高まりと即席診断キットへの注目の高まりが市場成長を牽引

感染予防を目的とした政府の取り組みが活発化していることが、市場成長の原動力になると予想されます。例えば、2023年7月22日、ライム病やダニ媒介性疾患と闘うための資金を強化するハドソンバレー州議会議員の法案が署名されました。ピート・ハルカム（Pete Harckham）、スー・セリノ（Sue Serino）両上院議員とディディ・バレット（Didi Barrett）下院議員によって提出された超党派の法案は、ダニ媒介性疾患の蔓延とより効果的に闘い、ニューヨーカーをダニ媒介性疾患から守るための資金を強化するもので、キャシー・ホーチュル（Kathy Hochul）知事によって署名されました。

すぐに使える診断キットの導入に力を入れるようになったことが、市場成長の原動力となっています。例えば、2023年3月21日、Jiangsu Bioperfectus Technologies Co., Ltd.は、BioPerfectusが独自に開発した6種類の新しいリアルタイムPCRキットを発表しました。バイオパーフェクタスは、世界の健康緊急事態に迅速に対応するため、パートナーのためにサンプルの前処理からPCR増幅分析まで、ベクター媒介性疾患総合診断ソリューションを提供しています。

ライム病診断薬の認知度の低さが市場成長の妨げになる可能性

ライム病診断薬の認知度の低さは、予測期間における市場の成長を阻害すると予想されます。ライム病診断のための検査やキットは数多く販売されているが、過疎地では入手が困難です。ライム病とその診断について知っている人はごく少数でしょう。農村部では、人々は病気とその診断に関連する知識が不足しています。

設備の整った診断センターがないため、病気の適切な診断ができず、市場の成長に影響を与える可能性があります。過疎地では診断検査が患者に行き届かず、病気の重症度が高まるため、市場成長に影響を与えます。したがって、市場は予測期間中に縮小すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
  • 技術進歩の拡大と新製品の導入
  • 政府のイニシアチブの高まりと即席診断キットへの注目の高まり
  • 抑制要因
  • ライム病診断薬に関する認識不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • パイプライン分析
  • 規制分析
  • ロシア・ウクライナ戦争影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 検査タイプ別

  • 血清学的検査
  • 尿中抗原検査
  • リンパ球形質転換検査
  • 免疫蛍光染色
  • 核酸検査
  • その他

第8章 検体別

  • 血液
  • 脳脊髄液
  • 尿
  • その他

第9章 エンドユーザー別

  • 病院
  • 診断センター
  • 外来手術センター
  • 公共／民間検査室
  • 開業医

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • T2 Biosystems, Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Bio-Rad Laboratories, Inc.
  • Oxford Immunotec USA, Inc.
  • Thermo Fisher Scientific Inc.
  • Quidel Corporation
  • Quest Diagnostics
  • BioMerieux India Private Limited
  • Diasorin S.p.A
  • Meridian Bioscience Inc.
  • Cortez Diagnostics Inc.

第13章 付録

目次
Product Code: CD2318

Overview

Global Lyme Disease Diagnostics Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.2 billion by 2030, growing with a CAGR of 4.3% during the forecast period 2023-2030.

Lyme disease diagnostics tests look for signs of infection in a sample of the blood or cerebrospinal fluid (CSF). CSF is a clear liquid that flows in and around the brain and spinal cord. The test checks samples for antibodies the immune system makes to fight the bacteria that cause Lyme disease. These diagnostic tests identify the antibodies produced by the immune system in response to the infection. Lyme disease diagnostics predict the likelihood of whether the patient is exposed to infected black-legged ticks.

Lyme Disease Diagnostics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global lyme disease diagnostics market size and growth, along with the latest trends, opportunities, and forecast till 2030.

Among all regions, the North America region is expected to hold the largest share of the global Lyme disease diagnostics market over the forecast period. North America shares a dominant position in the global Lyme disease diagnostics market. The serological test segment holds a significant position in the market share.

Dynamics

Increasing Technological Advancements and the Introduction of Novel Products are Expected to Drive Market Growth

The global Lyme disease diagnostics market growth is driven by several factors, such as various new innovations and products released in the market. According to the Lyme Disease Association, Lyme Disease is the most common tick-borne bacterial infection globally. The market is witnessing the launch and clearance of new validated diagnostic tests for accurate diagnosis of Lyme Disease.

For instance, on June 15, 2022, Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the launch of T-Detect Lyme. This is the company's second test to be made available from its growing T-Detect franchise.

The increase in novel launches and the introduction of various products for lyme disease diagnosis are expected to elevate the market growth. For instance, on October 26, 2022, Digital diagnostics company ixlayer announced it would produce CVS Health's branded at-home sample collection kits. Ixlayer's kits can test for Lyme disease, Vitamin D levels, thyroid function, and sexually transmitted infections. Thus, the above factors are expected to drive the market growth.

Growing Government Initiatives and Increased Focus on Ready-to-Use diagnostic Kits Drive Market Growth

The increased government initiatives in order to prevent infection are expected to drive market growth. For instance, on July 22, 2023, Hudson Valley Lawmakers' bill to bolster funding to combat Lyme and tick-borne diseases was signed into law. Bipartisan legislation advanced by State Senators Pete Harckham and Sue Serino, along with Assemblymember Didi Barrett, that aims to bolster funding to more effectively combat the spread and better protect New Yorkers against tick-borne illness has been signed into law by Governor Kathy Hochul.

The increased focus in introducing ready-to-use diagnostic kits is driving the market growth. For instance, on March 21, 2023, Jiangsu Bioperfectus Technologies Co., Ltd. has released six new Real-Time PCR Kits independently developed by BioPerfectus. BioPerfectus provides Vector-Borne Diseases Total Diagnostic Solutions from sample pre-processing to PCR amplification analysis for our partners to rapid response to a global health emergency.Thus, the initiatives taken by the government can enhance the market growth.

Lack of Awareness Associated with Lyme Disease Diagnostics is Expected to Hamper the Market Growth

Unawareness of Lyme disease diagnosis is expected to hinder the market's growth over the forecast period. A number of diagnostic tests and kits are available for lyme disease, which are not accessible by the under-developed areas. Only a few people may know about the disease and its diagnosis. In rural areas, people lack knowledge related to disease and its diagnosis.

The lack of diagnostic centers with fully equipped equipment cannot aid in the proper diagnosis of the disease, which can impact the market growth. The availability of diagnostic tests will not reach the patients in underdeveloped areas, and the severity of the disease will increase, thus impacting the market growth. Hence, the market is expected to decline over the forecast period.

Segment Analysis

The global lyme disease diagnostic market is segmented based on test type, test sample, end-user, and region.

Serological Tests Segment is Expected to Hold the Largest Market Share in the Global Lyme Disease Diagnostics Market

The global Lyme disease diagnostics market is segmented based on test type such as serological tests, urine antigen tests, lymphocytic transformation tests, immunofluorescent staining, nucleic acid tests, and others. The serological tests segment holds a dominant share over the others segments because of the presence of the identifiable number of antibodies in the blood against the pathogen. Serologic tests indicates the presence of both IgG and IgM antibodies to Borrelia burgdorferi in the blood of the individual.

The increased number of lsunches of the tests holds the segment in the dominant postion. For instance, on August 1, 2023, Incite Health, Inc., a CLIA-certified, CAP-accredited, high-complexity clinical laboratory specializing in immune system testing, announces the launch of a new paradigm in Lyme Disease testing, the ZEUS Scientific MTTT-2 ELISA system. Recently, the CDC updated its recommendation to state that serologic assays using a second ELISA test are an acceptable alternative to assays that use an immunoblot as a second test. Thus, holding the segment in the dominant position in the market share.

Geographical Penetration

North America Region Holds the Largest Market Share in the Global Lyme Disease Diagnostics Market

North America region is the dominating force in the global Lyme disease diagnostics market for the year 2022 due to the high prevalence of Lyme Disease. For instance, according to the CDC, it is estimated that approximately 476,000 people suffer Lyme disease each year in the United States, and every year, approximately 30,000 cases of Lyme disease are reported to the CDC by state health departments and the District of Columbia.

There are rising government and private institutes initiatives to treat and diagnose Lyme diseases in countries in the region. There are a majority of the companies developing Lyme disease diagnostics. Several institutes have increased their focus on developing novel diagnostic tests. Thus, the above factors are expected to drive the market growth in the region.

The increase in the government fundings is expected to drive the market growth in the region. For instance, on July 21, 2023, NIH awards announced that it will fund Post-Treatment Lyme Disease Syndrome research. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded five projects for research to understand better Post-treatment Lyme Disease Syndrome (PTLDS), which is a collection of symptoms, such as pain, fatigue, and difficulty thinking or "brain fog," which linger following standard treatment for Lyme disease. Thus, the above factors are expected to raise the region's market share.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Lyme disease diagnostics market. As countries grappled with lockdowns, the diagnostic and treatment procedures were significantly impacted, negatively impacting the whole market.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting the appointments and delaying the diagnosis. The hospitals and the diagnostic centers were closed for non-essential diagnosis of the diseases. The research and new developments have been halted due to COVID-19. Thus, it has negatively impacted the Lyme disease diagnostics market.

By Test Type

  • Serological Test
  • Urine Antigen Tests
  • Lymphocytic Transformation Test
  • Immunofluorescent Staining
  • Nucleic Acid Test
  • Others

By Test Sample

  • Blood
  • Cerebrospinal Fluid
  • Urine
  • Others

By End-User

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Public/Private Laboratories
  • Physician's Office

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On April 21, 2023, Moderna released new treatments for Lyme disease. Moderna has unveiled two novel mRNA vaccine candidates for Lyme disease in its development pipeline: mRNA-1982 and mRNA-1975. Lyme disease is a bacterial infection spread to humans by infected ticks, which can cause various symptoms, including a rash and a fever.

Competitive Landscape

The global Lyme disease diagnostics market is fragmented, with the presence of many local and international players. T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Oxford Immunotec USA, Inc., Thermo Fisher Scientific Inc., Quidel Corporation, Quest Diagnostics, BioMerieux India Private Limited, Diasorin S.p.A, Meridian Bioscience Inc., and Cortez Diagnostics Inc. are the leading companies with a significant market share.

Why Purchase the Report?

  • To visualize the global Lyme disease diagnostic market segmentation based on test type, test sample, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Lyme disease diagnostic market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Lyme disease diagnostic market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Test Sample
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
  • 4.2. Increasing technological advancements and the introduction of novel products
  • 4.3. Growing Government Initiatives and Increased Focus on Ready-to-Use diagnostic Kits
  • 4.4. Restraints
  • 4.5. Lack of awareness associated with Lyme disease diagnostics
    • 4.5.1. Opportunity
    • 4.5.2. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Pipeline analysis
  • 5.5. Regulatory Analysis
  • 5.6. Russia-Ukraine War Impact Analysis
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type
  • 7.2. Serological Test *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Urine Antigen Tests
  • 7.4. Lymphocytic Transformation Test
  • 7.5. Immunofluorescent Staining
  • 7.6. Nucleic Acid Test
  • 7.7. Others

8. By Test Sample

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 8.1.2. Market Attractiveness Index, By Test Sample
  • 8.2. Blood *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cerebrospinal Fluid
  • 8.4. Urine
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Public/Private Laboratories
  • 9.6. Physician's Office

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. T2 Biosystems, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bio-Rad Laboratories, Inc.
  • 12.3. Oxford Immunotec USA, Inc.
  • 12.4. Thermo Fisher Scientific Inc.
  • 12.5. Quidel Corporation
  • 12.6. Quest Diagnostics
  • 12.7. BioMerieux India Private Limited
  • 12.8. Diasorin S.p.A
  • 12.9. Meridian Bioscience Inc.
  • 12.10. Cortez Diagnostics Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us